The U.S. Food and Drug Administration (FDA) first approved an immune checkpoint inhibitor (ICI) therapy for melanoma in 2011, ipilimumab, which is an antibody that targets the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (10). This evidence concerns the gene CTLA4 and melanoma.